|
1
|
Pyörälä K, Laakso M and Uusitupa M:
Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab
Rev. 3:463–524. 1987.
|
|
2
|
Stumvoll M, Goldstein BJ and van Haeften
TW: Type 2 diabetes: principles of pathogenesis and therapy.
Lancet. 365:1333–1346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sibal L, Agarwal SC and Home PD: Carotid
intima-media thickness as a surrogate marker of cardiovascular
disease in diabetes. Diabetes Metab Syndr Obes. 4:23–34. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reaven GM: Banting lecture 1988. Role of
insulin resistance in human disease. Diabetes. 37:1595–1607. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun Q, Cornelis MC, Manson JE and Hu FB:
Plasma levels of fetuin-A and hepatic enzymes and risk of type 2
diabetes in women in the U.S. Diabetes. 62:49–55. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ix JH, Wassel CL, Kanaya AM, et al; Health
ABC Study. Fetuin-A and incident diabetes mellitus in older
persons. JAMA. 300:182–188. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ix JH, Biggs ML, Mukamal KJ, et al:
Association of fetuin-a with incident diabetes mellitus in
community-living older adults: the cardiovascular health study.
Circulation. 125:2316–2322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stefan N, Fritsche A, Weikert C, et al:
Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes.
57:2762–2767. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laughlin GA, Barrett-Connor E, Cummins KM,
Daniels LB, Wassel CL and Ix JH: Sex-specific association of
fetuin-A with type 2 diabetes in older community-dwelling adults:
the Rancho Bernardo Study. Diabetes Care. 36:1994–2000. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rasul S, Wagner L and Kautzky-Willer A:
Fetuin-A and angiopoietins in obesity and type 2 diabetes mellitus.
Endocrine. 42:496–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song A, Xu M, Bi Y, et al: Serum fetuin-A
associates with type 2 diabetes and insulin resistance in Chinese
adults. PLoS One. 6:e192282011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mathews ST, Chellam N, Srinivas PR, et al:
Alpha2-HSG, a specific inhibitor of insulin receptor
autophosphorylation, interacts with the insulin receptor. Mol Cell
Endocrinol. 164:87–98. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mathews ST, Singh GP, Ranalletta M, et al:
Improved insulin sensitivity and resistance to weight gain in mice
null for the Ahsg gene. Diabetes. 51:2450–2458. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schafer C, Heiss A, Schwarz A, et al: The
serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a
systematically acting inhibitor of ectopic calcification. J Clin
Invest. 112:357–366. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lorant DP, Grujicic M, Hoebaus C, et al:
Fetuin-A levels are increased in patients with type 2 diabetes and
peripheral arterial disease. Diabetes Care. 34:156–161. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eraso LH, Ginwala N, Qasim AN, et al:
Association of lower plasma fetuin-A levels with peripheral
arterial disease in type 2 diabetes. Diabetes Care. 33:408–410.
2010. View Article : Google Scholar
|
|
17
|
Alberti KG and Zimmet PZ: Definition,
diagnosis and classification of diabetes mellitus and its
complications. Part 1: diagnosis and classification of diabetes
mellitus, provisional report of a WHO consultation. Diabet Med.
15:539–553. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Freeman DJ, Norrie J, Sattar N, et al:
Pravastatin and the development of diabetes mellitus: evidence for
a protective treatment effect in the West of Scotland Coronary
Prevention Study. Circulation. 103:357–362. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment:
insulin resistance and beta-cell function from fasting plasma
glucose and insulin concentrations in man. Diabetologia.
28:412–419. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aydin M, Bulur S, Alemdar R, et al; Melen
Investigators. The impact of metabolic syndrome on carotid intima
media thickness. Eur Rev Med Pharmacol Sci. 17:2295–2301.
2013.PubMed/NCBI
|
|
21
|
Denecke B, Gräber S, Schäfer C, Heiss A,
Wöltje M and Jahnen-Dechent W: Tissue distribution and activity
testing suggest a similar but not identical function of fetuin-B
and fetuin-A. Biochem J. 376:135–145. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Zanotti I, Reilly MP, Glick JM,
Rothblat GH and Rader DJ: Overexpression of apolipoprotein A-I
promotes reverse transport of cholesterol from macrophages to feces
in vivo. Circulation. 108:661–663. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen HY, Chiu YL, Hsu SP, et al:
Association of serum fetuin A with truncal obesity and dyslipidemia
in non-diabetic hemodialysis patients. Eur J Endocrinol.
160:777–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roos M, Oikonomou D, von Eynatten M, et
al: Associations of fetuin-A levels with vascular disease in type 2
diabetes patients with early diabetic nephropathy. Cardiovasc
Diabetol. 9:482010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stefan N, Hennige AM, Staiger H, et al:
Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with
insulin resistance and fat accumulation in the liver in humans.
Diabetes Care. 29:853–857. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mori K, Emoto M, Yokoyama H, et al:
Association of serum fetuin-A with insulin resistance in type 2
diabetic and nondiabetic subjects. Diabetes Care. 29:4682006.
View Article : Google Scholar : PubMed/NCBI
|
